journal article
Jan 01, 2021
Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis
Topics
No keywords indexed for this article. Browse by subject →
References
39
[1]
Angiogenesis in cancer, vascular, rheumatoid and other disease. - PubMed - NCBI. Accessed September 20, 2019. https://www.ncbi.nlm.nih.gov/pubmed/7584949.
[2]
Anthony "Drug-induced vitiligo: a case/non-case study in Vigibase®, the WHO pharmacovigilance database" Fundam. Clin. Pharmacol. (2020) 10.1111/fcp.12558
[3]
Antiangiogenic therapy--evolving view based on clinical trial results. - PubMed - NCBI. Accessed September 4, 2019. https://www.ncbi.nlm.nih.gov/pubmed/22330688.
[4]
Anticoagulation Strategies in Patients With Cancer | JACC: Journal of the American College of Cardiology. Accessed September 20, 2019. http://www.onlinejacc.org/content/73/11/1336?_ga=2.99315356.342508733.1569030625-2083791483.1569030625.
10.1016/j.jacc.2019.01.017
[5]
Cancer and the prothrombotic state - The Lancet Oncology. Accessed September 20, 2019. https://www.thelancet.com/journals/lanonc/article/PIIS1470204501006192/fulltext.
[6]
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. - PubMed - NCBI. Accessed September 20, 2019. https://www.ncbi.nlm.nih.gov/pubmed/26529477.
[7]
Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. Accessed October 30, 2020. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
[8]
Common Terminology Criteria for Adverse Events (CTCAE). Published online 2017:155.
[9]
DerSimonian "Meta-analysis in clinical trials" Control. Clin. Trials (1986) 10.1016/0197-2456(86)90046-2
[10]
Guidance for the prevention and treatment of cancer-associated venous thromboembolism. Accessed September 20, 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715852/.
[11]
Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials | Annals of Oncology | Oxford Academic. Accessed September 4, 2019. https://academic.oup.com/annonc/article/24/12/2943/170848.
10.1093/annonc/mdt292
[12]
Bo Liu , Fengxia Ding , Yang Liu , Geng Xiong , Tao Lin , Dawei He , Yuanyuan Zhang , Deying Zhang , Guanghui Weincidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a com… - PubMed - NCBI. Accessed September 4, 2019. https://www.ncbi.nlm.nih.gov/pubmed/27602778.
[13]
JCI - Targeting cancer with kinase inhibitors. Accessed September 20, 2019. https://www.jci.org/articles/view/76094.
[14]
Mechanisms of adverse effects of anti-VEGF therapy for cancer. Accessed September 20, 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359962/.
[15]
Mechanisms of VEGF-Inhibitor Associated Hypertension and Vascular Disease. Accessed September 20, 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825002/.
[16]
Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors | Neurology. Accessed September 4, 2019. https://n.neurology.org/content/93/2/e143.
10.1212/wnl.0000000000007743
[17]
Non-kinase targets of protein kinase inhibitors | Nature Reviews Drug Discovery. Accessed September 20, 2019. https://www.nature.com/articles/nrd.2016.266.
[18]
Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. - PubMed - NCBI. Accessed September 4, 2019. https://www.ncbi.nlm.nih.gov/pubmed/25541349.
[19]
Peters "Assessing publication bias in meta-analyses in the presence of between-study heterogeneity" J. R. Stat. Soc. Ser. A Stat. Soc. (2010) 10.1111/j.1467-985x.2009.00629.x
[20]
QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. - PubMed - NCBI. Accessed September 4, 2019. https://www.ncbi.nlm.nih.gov/pubmed/25349964.
[21]
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. Accessed September 4, 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417086/.
[22]
Regorafenib in the treatment of metastatic colorectal cancer. - PubMed - NCBI. Accessed September 20, 2019. https://www.ncbi.nlm.nih.gov/pubmed/29569472.
[23]
Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials | Journal of Clinical Oncology. Accessed September 20, 2019. https://ascopubs.org/doi/10.1200/JCO.2009.27.2757.
[24]
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials - The Lancet Oncology. Accessed September 4, 2019. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70222-0/fulltext.
[25]
Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review. Accessed September 20, 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922760/.
[26]
Role of platelet-derived growth factors in physiology and medicine. - PubMed - NCBI. Accessed September 20, 2019. https://www.ncbi.nlm.nih.gov/pubmed/18483217.
[27]
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. - PubMed - NCBI. Accessed September 20, 2019. https://www.ncbi.nlm.nih.gov/pubmed/15585754.
[28]
Salem "Cardiovascular toxicities associated with ibrutinib" J. Am. Coll. Cardiol. (2019) 10.1016/j.jacc.2019.07.056
[29]
Schwarzer (2019)
[30]
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials
J. A. C. Sterne, A. J. Sutton, J. P. A. Ioannidis et al.
BMJ
2011
10.1136/bmj.d4002
[31]
Structural analysis of receptor tyrosine kinases. - PubMed - NCBI. Accessed September 20, 2019. https://www.ncbi.nlm.nih.gov/pubmed/10354703.
[32]
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. - PubMed - NCBI. Accessed September 20, 2019. https://www.ncbi.nlm.nih.gov/pubmed/27807302.
[33]
Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer | SpringerLink. Accessed September 20, 2019. https://link.springer.com/article/10.1007%2Fs40259-016-0194-1.
[34]
The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. - PubMed - NCBI. Accessed September 4, 2019. https://www.ncbi.nlm.nih.gov/pubmed/22532265.
[35]
The Hypercoagulable State of Malignancy: Pathogenesis and Current Debate. Accessed September 20, 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550339/.
[36]
Tumor angiogenesis: therapeutic implications. - PubMed - NCBI. Accessed September 17, 2019. https://www.ncbi.nlm.nih.gov/pubmed/4938153.
[37]
Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events. Accessed September 20, 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168784/.
[38]
VEGF-Targeted Therapy: Therapeutic Potential and Recent Advances. Accessed September 20, 2019. http://theoncologist.alphamedpress.org/content/10/6/382.full.
10.1634/theoncologist.10-6-382
[39]
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update | Journal of Clinical Oncology. Accessed September 20, 2019. https://ascopubs.org/doi/10.1200/JCO.19.01461.
Metrics
26
Citations
39
References
Details
- Published
- Jan 01, 2021
- Vol/Issue
- 157
- Pages
- 103186
- License
- View
Authors
Cite This Article
Avash Das, Somnath Mahapatra, Dhrubajyoti Bandyopadhyay, et al. (2021). Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis. Critical Reviews in Oncology/Hematology, 157, 103186. https://doi.org/10.1016/j.critrevonc.2020.103186
Related
You May Also Like
Epidermal growth factor-related peptides and their receptors in human malignancies
David S. Salomon, Ralf Brandt · 1995
2,044 citations
Use of comprehensive geriatric assessment in older cancer patients:
Martine Extermann, Matti Aapro · 2005
973 citations